close

Login

Library
Shopping Cart
Remember Me
Forgot password/Login issues?
loading animation for AJAX calls
 
 
Direct (781) 489-7301,  Toll Free (866) 285-7215

Search

Search
BCC Advance Search

Central Nervous System (CNS) Biomarkers: Technologies and Global Markets

  • Published: March 2013
  • |
  • Report Code: BIO074B

REPORT HIGHLIGHTS

The global CNS biomarker market was estimated at $1.7 billion in 2011 and nearly $2 billion in 2012. The market is projected to reach $5.1 billion by the end of the forecast period of 2012 to 2017, representing a compound annual growth rate (CAGR) of 20.7%.

This report provides:

  • An overview of the global market for central nervous system (CNS) biomarkers, which are measurable and quantifiable biological indicators that can be used to diagnose or predict disease, monitor disease progression, and predict treatment response.
  • Analyses of global market trends, with data from 2010 through 2012, and projections of compound annual growth rates (CAGRs) through 2017.
  • Evaluations of technologies such as genomics, proteomics, and imaging, and assessments of their advantages and disadvantages.
  • Discussion of CNS disease segments, prevalence, and gaps in treatment for Alzheimer’s disease, depression, Parkinson’s disease, multiple sclerosis, and others.
  • Patent analyses.
  • Comprehensive company profiles of major players.

SAMPLE FIGURE
GLOBAL CNS BIOMARKER MARKET BY APPLICATION, 2010-2017
($ MILLIONS)
GLOBAL CNS BIOMARKER MARKET BY APPLICATION, 2010-2017
To Contact us, click here  help


Source: BCC Research

Download Report Overview

REPORT SCOPE

SCOPE OF REPORT

Current and projected product forecasts during the forecast period of 2012 to 2017 are discussed.  New product launches will be discussed.  Revenue figures for 2011 are actual figures.  Revenue figures for 2012 are actual figures except where actual results have not been reported, due to the timing of the release of the report.

The report includes an analysis of leading and emerging CNS biomarkers and related drugs for each CNS disorder.  Profiles of producers of leading products and their specific products are provided.  The report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment.  The competitive environment is examined with a special focus on how new products will alter the quality of life of patients receiving CNS biomarker diagnostics and treatment with associated drugs.

Market figures are based on revenues at the manufacturers’ level and are projected at a 2012-dollar value.  Inflation is not computed into the projection figures.  Trends are assessed based on projected sales for existing products, for new product introductions, expanded markets for existing products and other factors affecting the market.

Included in this report are forecasts by product, product category and by company from 2012 through 2017.  The study is arranged to offer an overview of existing biomarker technology, drug markets for CNS diseases, drug and disease mechanism of action and companies, with forecasts broken down and covered by geographic region or country.

Patent and clinical trial information is reviewed for various candidate biomarkers.  The status of approval by the FDA and regulatory agencies in other countries of biomarker diagnostics in each segment is reviewed.

Figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change.  Revenue figures do not account for variation in local currencies.

All market share data presented is on a global basis, unless specifically noted.

ANALYST’S CREDENTIALS

Jackson Highsmith is a life sciences research consultant with more than 16 years of research experience.  Jackson has been consulting with specialty pharmaceuticals and large pharmaceutical industry players since 2007.  Prior to that, he worked at a large research and consulting firm where he focused on in-depth research; he also has worked at a large pharmaceutical company involved a wide range of medical therapeutics in early- and mid-stage drug development.


Download Report Overview

REPORT TOC

download table of contents
Pricing on the website is provided for single users and 2-5 users licenses only. All reports will be provided in a PDF format for download. To purchase multi-user licenses, please contact us at (+1)781-489-7301 or send an email to information@bccresearch.com
  Title/Chapter Name Pages Price
Central Nervous System (CNS) Biomarkers: Technologies and Global Markets 153 $6650
Chapter- 1: INTRODUCTION - Complimentary 5 $0
  Show Details
Chapter- 2: SUMMARY 3 $250
  Show Details
Chapter- 3: OVERVIEW 13 $848
  Show Details
Chapter- 4: TECHNOLOGIES 27 $1760
  Show Details
Chapter- 5: FACTORS INFLUENCING DEMAND FOR CNS BIOMARKERS 35 $2282
  Show Details
Chapter- 6: GLOBAL PHARMACEUTICAL MARKET 7 $456
  Show Details
Chapter- 7: CNS PHARMACEUTICAL AND BIOMARKER MARKETS 13 $848
  Show Details
Chapter- 8: CNS BIOMARKER PIPELINE 3 $196
  Show Details
Chapter- 9: BIOMARKER INDUSTRY STRUCTURE AND COMPETITIVE ANALYSIS 6 $391
  Show Details
Chapter- 10: CNS BIOMARKER CLINICAL TRIALS 9 $587
  Show Details
Chapter- 11: PATENT ANALYSIS 8 $522
  Show Details
Chapter- 12: MERGERS AND ACQUISITIONS, LICENSING AND PARTNERSHIP ACTIVITY IN 2012 3 $196
  Show Details
Chapter- 13: COMPANY PROFILES 21 $1369
  Show Details
 
  List of Tables
  List of Figures
Recommended combos for Forecast Model
+

BCC Research Report

Price: $6650

=

Total Price: $11650

Combo Price: $8000

Discount will be applied automatically after you will add the forecast model and any report to your cart.

 
Select License type:
buy now
download report overview
Want to find out more
about this report?
request more info
Get Notified
on all the latest research reports
Subscribe

Choose your License

loading animation for AJAX calls